Hospira Halts Shipment Of Two Drugs After FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Voluntary hold on Propofol, Liposyn will negatively impact 2010 sales, though acquisition of Orchid will help make up the difference.
You may also be interested in...
FDA Likely To Allow Outcomes Studies Post-Approval For Fat Emulsion Drugs
Agency will probably clear products based on non-inferiority studies with nutrition endpoints, but ultimately wants clinical outcomes trials.
Baxter’s Clinolipid Could Offer Safety Advantages While Mitigating Shortage
Though it doesn’t have a formal labeling claim, olive-oil based parenteral nutrition drug provides marketing advantages compared to soybean fat emulsions drugs, while helping to ease shortage.
FDA Calls for Greater Compliance With FAR Reporting Requirements
FDA examines field alert report data for early warnings of emerging quality issues, but finds only questions as many companies submit few if any FARs to the agency. Meanwhile, some manufacturers are finding benefits from reporting and dealing with drug defects and errors, improving corporate culture and in one case saving nearly $1 billion.